NCT07042594View on ClinicalTrials.gov

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

RBD1119

Subcutaneously Administered RBD1119 in Healthy Subjects.

DRUG

Placebo

Subcutaneously Administered Placebo in Healthy Subject.

Trial Locations (1)

Unknown

RECRUITING

CMAX Clinical Research, Adelaide

All Listed Sponsors
lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY